Leman Mutlu

@Info4PI ❤️ great to see Shiv

Honoring excellence in immunology 🧬✨ We were proud to present the 2025 Jeffrey Modell Prize to Dr. Patricia Rodriguez Morales, standing alongside Harvard Immunology Graduate Committee program directors Dr. Shiv Pillai and Dr. Wendy Garrett. This award celebrates a graduating PhD student whose research is advancing the future of immunology. The evening also featured opening remarks from Dr. Fred Alt, representing the Jeffrey Modell Foundation at this special annual event at Harvard Medical School. Here’s to the researchers, mentors, and leaders driving progress forward. 💙 #Immunology #MedicalResearch #JeffreyModellFoundation #PIAwareness #FutureOfMedicine #HarvardMedicalSchool

A 23 yr old man presents with high grade fever and cervical lymphadenopathy. ⤴️ WBC ⤵️Hgb and platelets Bone marrow ⤵️ Creatinine: 4.9 mg/dL LDH: 1800 What do you see in the BM 👇🏽 What's going on? Management?

@SilviaSchzRamon Wonderful! I hope you are coming to Maastricht- my trainee submitted a poster on hyposplenism- our question was when to think overlap- your paper will be well referenced! looking forward to speaking in person! One day!

Navigating primary and secondary immunodeficiency intersections: how to find IEI hidden within SID rdcu.be/fjuSq

@immunologydoc Infection risk immediate indeed- lost one patient to overwhelming sepsis- I am pro-primary prophylaxis with BiTEs

@LemMutlu At a system level, I think there is a debate about equity of use; how much Ig is going to be saved by delaying starting BCMA BiTEs at 4L until IgG<4 vs at initiation? It takes time to get ppl started anyway (esp SCIG) and inf risk is immediate.

The annual MDSAS immunoglobulin database report has landed and makes interesting reading. igd.mdsas.com/wp-content/upl… Secondary antibody deficiency is highlighted as a growth area; since 2013 there has been a 124% increase in people with SAD and 207% increase in IgRT use to treat

@immunologydoc A lot of immunomodulatory treatments are considered essential,with disproportionate scrutiny for cases requiring replacement doses it seems, replacement significantly lower in grams. Science base for the 2-4 g/kg, 6 weekly regimens, I am yet to understand.

Interestingly, the debate around whether to start myeloma patients on BCMA at initiation or when IgG<4 (inevitable) is highlighted as worthy of scrutiny. Yet, the progressive increase in Ig use for CIDP appears to have slipped under the radar.

We have just published our new best practice recommendations on the scope and clinical direction of immunology testing (G196), written by Dr Ravishankar Sargur. Find it here: ow.ly/LJvV50YVtZX #Immunology #RCPathBPR

Oi! Listen to the ID:IOTS Podcast? Like our crap? Well come support it on Patreon! Perks available! (Not many I'm busy) patreon.com/posts/welcome-… #IDxposts #idtwitter #infection #podcast

Primary immunodeficiencies are a group of 550+ conditions affecting immune function. They are not contagious but can lead to recurrent infections and long-term complications. 📊 Explore the World PI Week factsheet to learn more: worldpiweek.org/campaign-resou… #WorldPIWeek2026

A bit like all is physics, all in medicine is immunology; this is haematoimmunology joining hands with infection immunology, beautiful.

@IDiots_pod @EmpiricGame If you buy for everyone in the country we can split the shipping cost? Or we design our own- there comes the lawsuit now…

Holy crap @EmpiricGame, you getting a UK supplier?

Empiric Sanford Edition now available to buy!

✨ Day 2 of #DHM2026 in Antwerp delivered another inspiring and dynamic programme! The day began with the JM Educational Session, followed by parallel symposia addressing emerging mechanisms in drug hypersensitivity and drug hypersensitivity in the era of biologicals, sparking insightful discussions among participants. The morning continued with Plenary 2: Advances in Drug Hypersensitivity Diagnosis, highlighting the latest developments shaping both research and clinical practice. During the Poster Discussion Sessions, attendees engaged in lively exchanges across a broad spectrum of topics—from β-lactam allergy and NSAIDs to immediate and delayed reactions, desensitisation, paediatrics, and in vitro studies—showcasing the diversity and depth of current research. In the afternoon, the programme explored key areas including drug hypersensitivity in cancer and chemotherapy, primary mast cell disorders, and thought-provoking sessions on fact and fiction in β-lactam allergy as well as hypersensitivity in immunologically vulnerable populations. The day concluded with the Oral Abstract Prize Competition, celebrating outstanding contributions from emerging researchers in the field. As we look ahead to the final day, #DHM2026 continues to foster collaboration, innovation, and excellence in drug allergy.

@EAACI_HQ @EAACI_JM Amazing 3 days!

How are you using sirolimus in inborn errors of immunity? We are gathering insights on prescribing, monitoring and therapeutic drug monitoring across the UK to inform future national guidance. Please complete the survey here 👉 vist.ly/4vwqn

The @BSACandJAC BSAC Spring Conference is returning. This year our annual 2-day event is titled 'Advancing infection management – from global challenges to clinical innovation'. Find abstract submissions, the programme & registration here: ow.ly/ZmVN50YoXVX #pathology #cpd

@gulderenesra @TheEBMT @TheEBMT_Trainee My fellow poetry lover! Good translation: dünya kimseye kalmaz ❤️

Very excited to traveling to Madrid next week for @TheEBMT Annual Meeting from north but even more excited to see everyone again there!! #EBMT26 Come, let us all be friends for once, Let us make life easy on us, Let us be lovers and loved ones, The earth shall be left to no one.

A signed form isn't consent. It's paperwork. This week on The Allergist, we get into what meaningful consent actually looks like — and why done well, it is good medicine. Listen wherever you get your podcasts.